Facebook Tracking Image

National Comprehensive Cancer Network

Members Only
NCCN Oncology Research Program (ORP)
NCCN Lilly Abemaciclib Research Grant Opportunity: Submit by Friday, July 10, 2020
Study Proposal Submission-NCCN iEnvision
NCCN Pfizer Axitinib Research Grant Opportunity: Submit by Wednesday, August 12, 2020
NCCN Pfizer Biosimilars Grant Opportunity - Submit by Wednesday, September 9, 2020
ORP Recent News
ORP Scientific Publications
ORP for Industry
ORP Investigator Steering Committee
ORP Testimonials
Clinical Trials at NCCN Member Institutions
Find NCCN ORP Funded Clinical Trials at NCCN Member Institutions
ORP Grant History
Informed Consent Language Database
Points to Consider on the Best Practices for Biorepositories, Registries and Databases
NCCN Shared Resources
ORP Disclosure Policy
NCCN Collaboration with the National Business Group on Health
NCCN Health Information Technology Licensees
NCCN Policy Priorities

NCCN Research & Business Resources

Find a clinical trial >


The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) is one of the nation's premier institutions for the prevention, detection and treatment of cancer. The OSUCCC – James is one of only 45 comprehensive cancer centers in the United States as designated by the National Cancer Institute (NCI), a designation competitively maintained since 1976. After both of its last two NCI site visits for CCC re-designation, the OSUCCC – James earned a rating of “exceptional,” the NCI’s highest descriptor.  The OSUCCC – James also is a founding member of the National Comprehensive Cancer Network (NCCN), an alliance of 27 of the world's leading cancer centers that develops clinical practice guidelines to improve the quality and effectiveness of cancer care.

The OSUCCC – James benefits from the multidisciplinary expertise of more than 300 cancer researchers representing 12 of the 15 colleges at Ohio State, and from nearly 200 physician sub-specialists who collectively provide optimal treatment for patients with almost every form of cancer. These researchers and physicians collaborate to translate scientific discoveries into innovative therapies and prevention strategies. Their singular focus on cancer has led to numerous accomplishments that have changed the standards of care with respect to prevention, diagnosis and treatment.

December 2014 saw the opening  of  the new James Cancer Hospital and Solove Research Institute, a 1.1-million-square-foot, 21-story, 306-bed facility that replaced the original James and serves a model for 21st century cancer hospitals by integrating research and patient care more closely than ever before. Each inpatient unit has its own cancer focus. The oncologists, nurses, pharmacists and geneticists on each unit treat just that type of cancer, collaborating with researchers to examine every patient’s genes and tumor DNA to determine the best treatment and accelerate research discoveries.

The new James also contains:

  • a 36-bed blood and marrow transplant unit supported by a cellular-processing lab
  • an above-ground radiation oncology center with seven treatment vaults
  • a cancer surgical facility with 14 operating rooms, including six interventional operating suites and two suites connected to  a 3-Tesla MRI that enables patients to be imaged during surgery
  • translational research labs on each floor that bring physicians and researchers together to develop targeted treatments
  • one of only a few cancer emergency departments in the country. The department is integrated with The Ohio State University Wexner Medical Center’s main Emergency Department and includes 15 cancer-treatment stations staffed by physicians and nurses trained in oncology and emergency medicine
  • a cancer clinical trials unit experienced in conducting safe early-phase trials for qualifying patients
  • private patient rooms containing identical layouts to enhance safety in a setting that offers abundant natural light
  • chemotherapy suites at multiple locations


§ Foundation for the Accreditation of Cellular Therapy (FACT): The James' Blood and Marrow Transplant (BMT) program is accredited by the Foundation for the Accreditation of Cellular Therapy (FACT). FACT accredited the BMT program for allogeneic and autologous transplantation, including clinical, collection (apheresis and perioperative services for bone marrow harvest), and processing. FACT accreditation attests to the high quality of The James' BMT program.

§ Joint Commission Accreditation: The Joint Commission is an independent, not-for-profit organization that evaluates the quality and safety of care provided by healthcare organizations across the United States.

§ The American College of Surgeons Commission on Cancer: The American College of Surgeons Commission on Cancer (CoC) accredits cancer programs based on a comprehensive evaluation of: institutional and programmatic resources; program management and administration; clinical management; inpatient and outpatient care; supportive care services; research; quality management and improvement; cancer-data management; public education, prevention and detection; and professional education and staff support.

Clinical Trials

The James is one of only a few centers in the country approved by the National Cancer Institute to conduct both phase I and phase II clinical trials on novel anticancer drugs sponsored by the NCI. This gives patients access to some of the most advanced cancer treatments and clinical trials offered anywhere.